Keros Therapeutics: Analysts Project Substantial Growth Potential

Keros Therapeutics Inc (NASDAQ: KROS) is drawing significant market attention as CEO Jasbir Seehra prepares to present at the Wells Fargo Healthcare Conference. Trading at approximately $15.72 per share, the biotechnology firm has become a focal point for analysts who identify considerable upside in its equity valuation.

Robust Financial Turnaround and Cash Position

The company’s most recent quarterly report reveals a dramatic financial improvement. Keros Therapeutics reported a net profit of $148.5 million for Q1 2025, a stark contrast to the $43.1 million loss recorded during the same period last year. This impressive turnaround is further strengthened by a substantial cash reserve of $720.5 million in liquid assets. This financial security provides operational funding through 2029, a rare advantage in the capital-intensive biotechnology sector.

Strong Analyst Conviction and Price Targets

Market experts have expressed nearly unanimous optimism regarding Keros Therapeutics’ prospects. The average price target among analysts stands at $30.00, representing a potential appreciation of over 90% from current levels. Even more bullish projections reach as high as $102.00 per share, while the most conservative estimate sits at $15.00. The consensus rating of 2.50 falls between “Hold” and “Buy,” with a notable absence of “Sell” recommendations across analyst coverage.

Should investors sell immediately? Or is it worth buying Keros Therapeutics Inc?

Promising Pipeline and Strategic Developments

The foundation for this optimism lies in the company’s developmental pipeline. KER-065, the lead drug candidate targeting neuromuscular diseases, has demonstrated positive Phase 1 data. The program is scheduled to advance to Phase 2 trials in early 2026.

Simultaneously, the Board of Directors is evaluating strategic alternatives to enhance shareholder value. Potential partnerships or acquisition interest in any of the pipeline assets could provide additional catalysts for the stock price.

The coming months present several critical milestones. Results from the Phase 2 TROPOS study for Cibotercept are anticipated in the second quarter of 2025, representing a potential significant catalyst for the company’s valuation.